Animal experiments and cohort studies also suggest potential benefits of SGLT2 inhibitors in non-alcoholic fatty liver disease and hepatocellular carcinoma [22, 43, 44]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.